Literature DB >> 29805675

Dioscin suppresses the viability of ovarian cancer cells by regulating the VEGFR2 and PI3K/AKT/MAPK signaling pathways.

Xianqing Guo1, Xiao Ding2.   

Abstract

Diosgenin is a natural steroidal saponin that is extracted from a range of sources, including from fenugreek. It is a critical raw material in the synthesis of steroid hormone drugs, exhibiting antitumor, anti-inflammatory, antioxidation and a number of other significant pharmacological actions, possessing high pharmaceutical value. The aim of the present study was to investigate the effects of dioscin suppression on ovarian cancer cell growth and the mechanism of apoptosis induction by dioscin in ovarian cancer cells. The results of the present study demonstrated that dioscin decreased viability and induced apoptosis in SKOV3 human ovarian cancer cells in a dose-dependent manner. Dioscin significantly increased caspase-3 and caspase-9 activity, and increased the protein expression of Bax and cleaved poly(ADP-ribose) polymerase in SKOV3 cells. In addition, dioscin significantly suppressed vascular endothelial growth factor receptor (VEGFR)2, phosphoinositide 3-kinase (PI3K), phosphorylated AKT and phosphorylated p38 mitogen-activated protein kinase (MAPK) protein expression in SKOV3 cells. Taken together, to the best of our knowledge, the present study demonstrated for the first time that dioscin suppresses cell viability in ovarian cancer cells by regulating the VEGFR2 and PI3K/AKT/MAPK signaling pathways.

Entities:  

Keywords:  dioscin; mitogen-activated protein kinase; ovarian cancer cells; phosphoinositide 3-kinase/protein kinase B; vascular endothelial growth factor receptor 2

Year:  2018        PMID: 29805675      PMCID: PMC5958686          DOI: 10.3892/ol.2018.8454

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  31 in total

1.  Upregulated CTHRC1 promotes human epithelial ovarian cancer invasion through activating EGFR signaling.

Authors:  Jun Ye; Wei Chen; Zhi-Yong Wu; Jin-Hui Zhang; He Fei; Li-Wen Zhang; Ya-Hui Wang; Ya-Ping Chen; Xiao-Mei Yang
Journal:  Oncol Rep       Date:  2016-10-24       Impact factor: 3.906

2.  Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells.

Authors:  Sirin A I Adham; Ifat Sher; Brenda L Coomber
Journal:  Lab Invest       Date:  2010-03-01       Impact factor: 5.662

3.  Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.

Authors:  Yulan Ren; Tingyan Shi; Rong Jiang; Sheng Yin; Pan Wang; Rongyu Zang
Journal:  Int J Gynecol Cancer       Date:  2015-10       Impact factor: 3.437

4.  Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial.

Authors:  C Falandry; B Weber; A-M Savoye; F Tinquaut; O Tredan; E Sevin; L Stefani; F Savinelli; M Atlassi; J Salvat; E Pujade-Lauraine; G Freyer
Journal:  Ann Oncol       Date:  2013-09-22       Impact factor: 32.976

5.  Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.

Authors:  Harriet O Smith; James Moon; Sharon P Wilczynski; Amy D Tiersten; Edward V Hannigan; William R Robinson; Saul E Rivkin; Garnet L Anderson; P Y Liu; Maurie Markman
Journal:  Gynecol Oncol       Date:  2009-05-23       Impact factor: 5.482

6.  Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer.

Authors:  Srinivas Ganta; Amit Singh; Niravkumar R Patel; Joseph Cacaccio; Yashesh H Rawal; Barbara J Davis; Mansoor M Amiji; Timothy P Coleman
Journal:  Pharm Res       Date:  2014-03-19       Impact factor: 4.200

7.  Targeting EGFR and PI3K pathways in ovarian cancer.

Authors:  S Glaysher; L M Bolton; P Johnson; N Atkey; M Dyson; C Torrance; I A Cree
Journal:  Br J Cancer       Date:  2013-09-10       Impact factor: 7.640

8.  The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.

Authors:  Boh-Ram Kim; Kyungsil Yoon; Hyun-Jung Byun; Seung Hee Seo; Seung-Hoon Lee; Seung Bae Rho
Journal:  Oncotarget       Date:  2014-08-15

9.  Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) in Patients With Serous Ovarian Carcinoma and Their Clinical Significance.

Authors:  Reza Ranjbar; Foroogh Nejatollahi; Ahmad Sina Nedaei Ahmadi; Hossein Hafezi; Akbar Safaie
Journal:  Iran J Cancer Prev       Date:  2015-08-24

10.  Betacellulin induces Slug-mediated down-regulation of E-cadherin and cell migration in ovarian cancer cells.

Authors:  Jianfang Zhao; Christian Klausen; Xin Qiu; Jung-Chien Cheng; Hsun-Ming Chang; Peter C K Leung
Journal:  Oncotarget       Date:  2016-05-17
View more
  7 in total

Review 1.  Co-Targeting Tumor Angiogenesis and Immunosuppressive Tumor Microenvironment: A Perspective in Ethnopharmacology.

Authors:  Jianbo Zhou; Li Wang; Cheng Peng; Fu Peng
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

2.  Health Beneficial Phytochemicals in Dioscorea caucasica Lipsky Leaves and Tubers and Their Inhibitory Effects on Physiologically Important Enzymes.

Authors:  Aušra Adomėnienė; Audrius Pukalskas; Ona Ragažinskienė; Petras Rimantas Venskutonis
Journal:  Plants (Basel)       Date:  2022-05-18

3.  RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply.

Authors:  Liang Kong; Fu-Yi Cai; Xue-Min Yao; Ming Jing; Min Fu; Jing-Jing Liu; Si-Yu He; Lu Zhang; Xin-Ze Liu; Rui-Jun Ju; Xue-Tao Li
Journal:  Cancer Sci       Date:  2020-01-18       Impact factor: 6.716

4.  Development of an Oriental Medicine Discrimination Method through Analysis of Steroidal Saponins in Dioscorea nipponica Makino and Their Anti-Osteosarcoma Effects.

Authors:  Joo Tae Hwang; Ki-Sun Park; Jin Ah Ryuk; Hye Jin Kim; Byoung Seob Ko
Journal:  Molecules       Date:  2019-11-06       Impact factor: 4.411

5.  Dioscin inhibits SCC15 cell proliferation via the RASSF1A/MST2/YAP axis.

Authors:  Hui Tian; Xiyan Chen; Yafei Zhang; Ying Wang; Xucheng Fu; Weiting Gu; Yong Wen
Journal:  Mol Med Rep       Date:  2021-03-31       Impact factor: 2.952

6.  Yang-Yin-Jie-Du decoction overcomes gefitinib resistance in non-small cell lung cancer via down-regulation of the PI3K/Akt signalling pathway.

Authors:  Shu-Yi Chen; Gao-Chen-Xi Zhang; Qi-Jin Shu
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

7.  Elucidating tumor heterogeneity from spatially resolved transcriptomics data by multi-view graph collaborative learning.

Authors:  Chunman Zuo; Yijian Zhang; Chen Cao; Jinwang Feng; Mingqi Jiao; Luonan Chen
Journal:  Nat Commun       Date:  2022-10-10       Impact factor: 17.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.